PER-011-19招募中未知
RANDOMIZED, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS SULBACTAM-ETX2514 IN THE TREATMENT OF PATIENTS WITH INFECTIONS CAUSED BY ACINETOBACTER BAUMANNII-CALCOACETICUS COMPLEX
ENTASIS THERAPEUTICS, INC,0 个研究点目标入组 24 人开始时间: 2019年7月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •General Inclusion Criteria:
- •1. A signed informed consent form (ICF). If a study patient is unable to provide informed consent due to their medical condition, the patient’s legally authorized representative may consent on behalf of the study patient, as permitted by local law and institutional Standard Operating Procedures;
- •2. Male or female older than 18 years of age;
- •3. A confirmed diagnosis of a serious infection and the expectation, in the judgment of the Investigator, that the patient’s infection will require treatment with IV antibiotics;
- •4. A known infection caused by ABC (bacteremia, HABP, VABP, cUTI or AP, or surgical or post-traumatic wound infections) as either a single pathogen or member of a polymicrobial infection based on evidence from culture or, if available, rapid diagnostic test from a sample collected within 72 hours prior to randomization (HABP/VABP patients), AND 1 of the following:
- •a. Has received no more than 48 hours of effective empiric therapy prior to enrollment;
- •b. Is clinically failing prior treatment regimens (ie, clinical deterioration or failure to improve after at least 48 hours of antibiotic treatment);
- •Note: Rapid testing of respiratory specimens utilizing FilmArray 2.0 BPP technology may be used to enable early identification of ABC pneumonia. Patients can be randomized based on the results of the BPP rapid test while awaiting results of cultures from the local laboratory. However, if the respiratory sample does not grow ABC in the local
- •microbiology laboratory culture, these patients will be withdrawn from the study drug treatment.
- •5. Expectation, in the judgment of the Investigator, that the patient will survive at least 72 hours with effective antibiotic therapy and appropriate supportive care for the anticipated duration of the study;
- •6. Women of childbearing potential (ie, not post-menopausal or surgically sterilized) must have a negative serum pregnancy test before randomization. Participating women of childbearing potential must be willing to consistently use 2 highly effective methods of contraception (ie, condom, combined oral contraceptive, implant, injectable, indwelling intrauterine device, or a vasectomized partner) from Screening until at least 30 days after administration of the last
- •dose of study drug; and
- •7. Male participants must be willing to use condoms during sexual intercourse from Screening until at least 90 days after administration of the last dose of study drug.
- •Part A-Specific Inclusion Criteria
- •1. APACHE II score between 10 and 30, inclusive, OR SOFA score more than or equal to 7 at the time of diagnosis of infection. Patients who might be eligible for Part A and are not being treated in an intensive care unit and cannot have an APACHE II or SOFA score performed should have a qSOFA score more than or equal to 2 for enrollment in Part A; and
- •2. Diagnosed with HABP, VABP, and/or bacteremia according to protocol section 4.1.2
- •Part B-Specific Inclusion Criteria
- •1. Has an infection caused by ABC organisms known to be resistant to colistin (defined as MIC more or equal to 4 mg/L by a non-agar based method);
- •For known colistin-resistant infections, the following must be satisfied:
- •a. Has a known resistant infection based on evidence from culture and susceptibility testing by a non-agar based method within 72 hours prior to randomization, alone or as a single organism of a polymicrobial infe
排除标准
- •Exclusion criteria
- •1. Presence of suspected or confirmed deep-seated infection, including lung abscess in patients with pneumonia, that is not planned on being drained within 24 hours after randomization;
- •2. Evidence of active concurrent community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila, respiratory syncytial virus, influenza and parainfluenza viruses, Middle East respiratory syndrome coronavirus, etc
- •3. Presence of suspected or confirmed osteomyelitis, endocarditis, or meningitis, as determined by history and/or physical examination;
- •4. Irremovable implantable device or line thought to be the potential source of infection;
- •5. Sustained shock with persisting hypotension requiring vasopressors to maintain mean arterial pressure (MAP) more than 60 mmHg AND having a serum lactate >2 mmol/L (18 mg/dL) despite adequate volume resuscitation;
- •6. For patients to be enrolled with the primary indication of HABP or VABP, any of the following conditions:
- •a. Diagnosis of ventilator-associated tracheobronchitis; or
- •b. Inability to provide proper respiratory specimens for culture. Respiratory samples from expectorated or induced sputum should show <10 squamous epithelial cells and >25 polymorphonuclear neutrophils per 100per field;
- •7. For patients to be enrolled with the primary indication of cUTI or AP, any of the urologic conditions listed in section 4.2 item 7
- •8. Moribund patients or patients with evidence of immediately life-threatening disease where, in the opinion of the Investigator, the patient is unlikely to survive more than 72 hours after Day 1;
- •9. Pregnant or breastfeeding women;
- •10. APACHE II score >30 at the time of diagnosis of infection
- •11. Receiving chronic hemodialysis or peritoneal dialysis;
- •12. Known seizure disorder requiring current treatment with antiseizure medication that, in the opinion of the Investigator, would prohibit the patient from complying with the protocol.
- •13. Requirement for continuing treatment with probenecid, methotrexate, ganciclovir, valproic acid, or divalproex sodium during the study;
- •14. Evidence of significant hepatic disease or dysfunction, including known acute viral hepatitis, hepatic cirrhosis, hepatic failure, chronic ascites, or hepatic encephalopathy;
- •15. Aspartate aminotransferase (AST) or ALT >3 upper limit of normal (ULN) AND total bilirubin >2 ULN at Screening;
- •16. Requirement at the time of randomization for any reason, or likely to require during the patient’s participation in the study (from randomization through the LFU Visit), for additional systemic antimicrobial therapy (including Gram negative antibacterial, antiviral, antimycobacterial, or antifungal therapy) other than study drug, with the exception of a single oral dose of any antifungal treatment for vaginal candidiasis
- •17. Requirement for inhaled antibiotics;
- •18. Known history of human immunodeficiency virus infection and known recent CD4 count <200/mm3 within the last year or presence of significant immunologic disease or dysfunction
- •19. Presence of neutropenia (absolute neutrophil count <500/mm3) obtained from a local laboratory at Screening;
- •20. A QT interval corrected using Fridericia’s formula (QTcF) more than 480 msec
- •21. History of significant hypersensitivity or allergic reaction to any BL, any contra
研究者
相似试验
尚未招募
3 期
Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter baumannii-calcoaceticus ComplexCTRI/2019/07/020401Entasis Therapeutics
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Efficacy and Safety of Sulbactam-ETX2514, a New Drug in the Treatment of Patients With ABC Infections Caused by Acinetobacter baumannii-calcoaceticus ComplexInfections Caused by Acinetobacter baumannii-calcoaceticus ComplexMedDRA version: 20.0 Level: LLT Classification code 10003999 Term: Bacteremia System Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0 Level: HLT Classification code 10046577 Term: Urinary tract infections System Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1 Level: PT Classification code 10037597 Term: Pyelonephritis acute System Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0 Level: LLT Classification code 10076918 Term: Hospital acquired pneumonia System Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1 Level: LLT Classification code 10065153 Term: Ventilator associated pneumonia System Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0 Level: LLT Classification code 10078408 Term: Surgical site infection System Organ Class: 10021881 - Infections and infestationsEUCTR2018-002526-23-GREntasis Therapeutics246
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Efficacy and Safety of Sulbactam-ETX2514, a New Drug in the Treatment of Patients With ABC Infections Caused by Acinetobacter baumannii-calcoaceticus ComplexEUCTR2018-002526-23-LTEntasis Therapeutics228
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Efficacy and Safety of Sulbactam-ETX2514, a New Drug in the Treatment of Patients With ABC Infections Caused by Acinetobacter baumannii-calcoaceticus ComplexInfections Caused by Acinetobacter baumannii-calcoaceticus ComplexMedDRA version: 20.0Level: LLTClassification code 10003999Term: BacteremiaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: PTClassification code 10037597Term: Pyelonephritis acuteSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10076918Term: Hospital acquired pneumoniaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10065153Term: Ventilator associated pneumoniaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10078408Term: Surgical site infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-002526-23-HUEntasis Therapeutics308
招募中
不适用
A CLINICAL TRIAL TO STUDY THE EVALUATION OF CHANGE IN QUALITY OF LIFE IN PATIENTS WITH SOLID TUMORS UNDERGOING CHEMOTHERAPY-BY GUIDELINES BASED SELF MANAGEMENT OF SIDE EFFECTSCTRI/2010/091/000232I86